Previous close | 5,694.00 |
Open | 5,696.00 |
Bid | 5,668.00 x N/A |
Ask | 5,672.00 x N/A |
Day's range | 5,666.00 - 5,726.00 |
52-week range | 5,400.00 - 6,824.00 |
Volume | |
Avg. volume | 1,350,759 |
Market cap | 40.598B |
Beta (5Y monthly) | 0.18 |
PE ratio (TTM) | 13.35 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 1.75 (3.05%) |
Ex-dividend date | 04 Aug 2022 |
1y target est | N/A |
Yahoo Finance health care reporter Anjalee Khemlani shares the latest on the ongoing baby formula shortage and how it may extend into spring 2023.
The soap and cleaning materials industry battles headwinds from elevated logistics, input and manufacturing costs. Innovation, digital growth and brand building are likely to drive players like PG, RBGLY, HENKY, CHD and CLX.
LONDON (Reuters) -The near year-long infant formula shortage in the United States that prompted the intervention of the White House is likely to "persist" until spring, according to Reckitt Benckiser, the maker of what is now the biggest brand in the market, Enfamil. Panicked parents had earlier this year emptied the baby formula aisles at supermarkets after former top U.S. manufacturer Abbott Laboratories in February recalled dozens of types of its Similac, Alimentum and EleCare formulas. Supermarkets like Target and Walgreens Boots Alliance were forced to limit sales, putting pressure on the Biden administration to address the crisis.